What's new

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0117/2024

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0117/2024

Jun 11, 2025 - 16:25
 0
Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0117/2024
Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0117/2024
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Leflunomide Zentiva (p...

Next Article

EMEA-002362-PIP02-19-M03

Related Posts

Human medicines European public assessment report (EPAR): Capvaxive, pneumococcal polysaccharide conjugate vaccine (21-valent), Date of authorisation: 24/03/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 10, 2025  0

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 5, 2025  0

Referral: Azithromycin-containing medicinal products for systemic use, azithromycin Article 31 referrals CHMP opinion, 22/05/2025, 23/05/2025

Referral: Azithromycin-containing medicinal products fo...

May 23, 2025  0